Predicting Early Failure after Adjuvant Chemotherapy in High-Risk Breast Cancer Patients with Extensive Lymph Node Involvement
Open Access
- 1 July 2004
- journal article
- clinical trial
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (13) , 4457-4463
- https://doi.org/10.1158/1078-0432.ccr-03-0054
Abstract
Purpose: There is limited knowledge of risk factors for breast cancer recurrence within 2 years. This study aimed to predict early failure and identify high-risk patients for prognostic and therapeutic purposes. Experimental Design: We studied 739 patients from a randomized trial who were Results: Early failure occurred in 19% (n = 137). Median survival after early failure was limited to 0.7 year. Estrogen and progesterone receptor negativity and visceral relapse predicted poor prognosis. Early failure was associated with young age, large tumors, high histological grade, angio-invasion, apical node metastasis, and ≥10 involved nodes. Estrogen receptor, progesterone receptor, and p27 negativity; HER2 overexpression; and p53 positivity also predicted early failure. The surgical or chemotherapy regimen and histological type did not. The same parameters except tumor size were associated with early death. Grade III, ≥10 involved nodes, and estrogen receptor negativity were independently associated with early failure and together identified a subset of patients (7%) with 3-fold increased early failure and 5-fold increased early death. Conclusions: Early failure is associated with poor survival. The combination of three commonly determined parameters constitutes a strong predictive model for early failure and death.Keywords
This publication has 30 references indexed in Scilit:
- High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for High-Risk Breast CancerNew England Journal of Medicine, 2003
- HER2/neuAmplification in Breast CancerAmerican Journal of Clinical Pathology, 2002
- Breast carcinoma in women age 25 years or lessCancer, 2002
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosisEuropean Journal Of Cancer, 1995
- TP53 mutations and breast cancer prognosis: Particularly poor survival rates for cases with mutations in the zinc‐binding domainsGenes, Chromosomes and Cancer, 1995
- Effect of systemic adjuvant treatment on first sites of breast cancer relapseThe Lancet, 1994
- pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐upHistopathology, 1991
- Advanced Breast Cancer: A randomised trial of epidoxorubicin at two different dosages and two administration systemsActa Oncologica, 1989
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987